Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call Transcript

Nov 26, 2024 / 09:30PM GMT
Release Date Price: €17.8 (+0.82%)
Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call throughout today's recorded presentation. (Operator Instructions) and I had a conference over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead Vince.

Vince Anzalone
Arrowhead Pharmaceuticals Inc - Investor Relations

Thank you. Good afternoon. Thank you for joining us today to discuss Arrowhead's results for its fiscal 2024 year ended, September 30th 2024 with us today from management are President and CEO Doctor Chris Anzalone who will provide an overview of the quarter. Doctor Bruce Gi, Interim Chief, medical scientists, who will provide an update on our cardio metabolic pipeline. Andy, senior Vice President and head of global cardiometabolic franchise who will provide an update on commercialization activities. Dr James Hamilton, chief of discovery and translational medicine, who will discuss our earlier stage development programs. And Ken Moskowsky, Chief Financial Officer who will give a review of the financials, we will then open the call to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot